Beware the BCG Failures: A Review of One Institution's Results

Lockyer, C.R.; Sedgwick, James E.C; Gillatt, David

doi:10.1016/s0302-2838(02)00491-8

Cited by 23 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, long-term BCG maintenance therapy was associated with 29.6% tumor recurrence and 18% tumor progression, which is significantly less than the 51% recurrence rate found by Lockyer et al after short-term BCG therapy 7 . In another study the recurrence rate ranged between 20% and 40% depending on the tumor-risk factors and the period of follow-up after long-term BCG therapy 5 .…”

Section: Discussioncontrasting

confidence: 67%

Failure of Bacillus Calmette Guerin (BCG) therapy for the treatment of bladder cancer: Al-Azhar experience

El-Mallah

2009

Afr J Urol

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 67%

Failure of Bacillus Calmette Guerin (BCG) therapy for the treatment of bladder cancer: Al-Azhar experience

El-Mallah

2009

Afr J Urol

View full text Add to dashboard Cite

“…139 The tumor status at the initial surveillance cystoscopy after BCG treatment is an important prognostic factor. 140 Data supporting the use of standard intravesical chemotherapeutic agents such as thiotepa, doxorubicin, and MMC in patients who failed initial BCG therapy are limited. Malmstrom et al looked at MMC in patients who had failed BCG and reported a 19% 3-year disease-free rate among intermediate and high-risk patients.…”

Section: Nonmuscle-invasive Diseasementioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

300

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

“…Solsona et al [15] pointed out that early recurrence after intravesical BCG treatment was an indicator of progression, and radical cystectomy should be offered to such patients. Lockyer et al [16] have investigated the prognostic value of 3-month recurrence in patients with high-risk tumors who received intravesical BCG treatment, and reported that 60% of the patients who had a positive cystoscopy in the 3rd month progressed and 40% died of disease, compared to 12 and 5%, respectively, for patients who had a negative cystoscopy.…”

Section: Discussionmentioning

confidence: 99%

Intermediate-Risk Group in Patients with Transitional Cell Carcinoma of the Bladder: Prediction of High-Risk Patients in This Heterogeneous Group

Yencilek

Önal²,

Erözenci³

et al. 2009

Urol Int

View full text Add to dashboard Cite

Objective: To determine whether recurrence at first follow-up cystoscopy predicts future recurrence in patients with an intermediate risk of superficial bladder cancer. Methods: In total, 304 patients were classified as low (n = 60), intermediate (n = 177) or high risk (n = 67) based on the primary pathological/clinical findings, as previously described in literature. The intermediate-risk group was further divided into 2 subgroups based on recurrence at the first follow-up cystoscopy: A (recurrence negative) and B (recurrence positive). Results: The mean recurrence rates of low-, intermediate- and high-risk patients were 1.76, 6.41 and 9.49, respectively (p < 0.05). Similarly, the difference in the recurrence rates between subgroups A (4.37) and B (9.12) was found to be statistically significant (p = 0.00). Additionally, while the difference between the low-risk group and subgroup A was statistically significant (p = 0.008), there was no significance between subgroup B and the high-risk group (p = 0.892). In the multivariate analysis, the most significant prognostic parameter for recurrence was the outcome of the first follow-up cystoscopy, followed by tumor multiplicity and grade. Conclusions: Patients showing recurrence at first follow-up cystoscopy in the intermediate-risk group should be classified as high-risk patients and treated accordingly.

show abstract

Beware the BCG Failures: A Review of One Institution's Results

Cited by 23 publications

References 10 publications

Failure of Bacillus Calmette Guerin (BCG) therapy for the treatment of bladder cancer: Al-Azhar experience

Failure of Bacillus Calmette Guerin (BCG) therapy for the treatment of bladder cancer: Al-Azhar experience

Bladder Cancer in 2010: How Far have We Come?

Intermediate-Risk Group in Patients with Transitional Cell Carcinoma of the Bladder: Prediction of High-Risk Patients in This Heterogeneous Group

Contact Info

Product

Resources

About